Patient Compliance to a New Enteric-Coated Weekly Formulation of Fluoxetine During Continuation Treatment of Major Depressive Disorder
J Clin Psychiatry 2000;61(12):928-932
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: A new formulation of enteric-coated
fluoxetine given once weekly could be a useful option for the
long-term treatment of depression, but compliance to once-weekly
fluoxetine treatment has not been assessed.
Method: Patients were adults from the United
Kingdom who had responded to fluoxetine treatment for a current
episode of depression (DSM-IV criteria). In the baseline
assessment phase, all patients (N = 117) were continued on 20 mg
of open-label fluoxetine once daily for 4 weeks. In the follow-up
phase, patients (N = 109) were randomly assigned to once-weekly
or once-daily fluoxetine for 3 months. Patient compliance was
monitored by electronic devices during both phases of the study.
Results: Compliance to once-weekly fluoxetine
treatment was higher than compliance to once-daily fluoxetine
(85.9% vs. 79.4%, respectively).
Conclusion: Once-weekly fluoxetine treatment
allows for new flexibility for both the clinician and the
patient, and this study alleviates the concern that patients will
forget weekly doses.